In its Q2 2026 filing, Progyny reported continued growth in covered members and increasing utilization rates of its fertility services, signaling strong market demand and effective member engagement. The company leverages an integrated model combining third-party administration (TPA) and pharmacy benefit management (PBM), supported by Patient Care Advocates, which differentiates its offering within the fertility benefits niche. However, operating within a fragmented regulatory landscape involving multiple states’ licensing regimes and evolving PBM oversight introduces ongoing legal and operational risks that could impact growth and cost structure. International expansion contributes a nascent but growing revenue stream. Solid liquidity positions the company to sustain investments amid these challenges.